Abstract
Usually, wherever breast STAT5a is present, PRLR is reduced; without STAT5a PRLR becomes abundant. Five breast lesions essentially lacking both were tested immunohistochemically for PRLR isoforms. The intermediate isoform was essentially only detected in these lesions. In some breast lesions PRLR isoforms may be involved in JAK/STAT pathway disturbances.
Keywords: Breast, STAT5a, PRLR, Immunohistochemistry, Intermediate Isoform
Protein & Peptide Letters
Title: Cells with Minimal Expression of the JAK/STAT Pathway Related Proteins STAT5a and the Prolactin Receptor: Evidence of an Alternate Prolactin Receptor Isoform in Breast Disease
Volume: 17 Issue: 1
Author(s): G. L. Bratthauer, M. D. Stamatakos and T. N. Vinh
Affiliation:
Keywords: Breast, STAT5a, PRLR, Immunohistochemistry, Intermediate Isoform
Abstract: Usually, wherever breast STAT5a is present, PRLR is reduced; without STAT5a PRLR becomes abundant. Five breast lesions essentially lacking both were tested immunohistochemically for PRLR isoforms. The intermediate isoform was essentially only detected in these lesions. In some breast lesions PRLR isoforms may be involved in JAK/STAT pathway disturbances.
Export Options
About this article
Cite this article as:
Bratthauer L. G., Stamatakos D. M. and Vinh N. T., Cells with Minimal Expression of the JAK/STAT Pathway Related Proteins STAT5a and the Prolactin Receptor: Evidence of an Alternate Prolactin Receptor Isoform in Breast Disease, Protein & Peptide Letters 2010; 17 (1) . https://dx.doi.org/10.2174/092986610789909467
DOI https://dx.doi.org/10.2174/092986610789909467 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of the Healthy Dietary Intake in Women with Human Papilloma Virus
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Potentiation of Anti-Cancer Treatment by Modulators of Energy Metabolism
Current Pharmaceutical Biotechnology Bone: A Fertile Soil for Cancer Metastasis
Current Drug Targets Harvesting New Therapeutic Avenues with Stem Cell Applications
Current Neurovascular Research Q-TOF LC/MS-based Untargeted Metabolomics Approach to Evaluate the Effect of Folate-Conjugated Cyclodextrins on Triple-Negative Breast Cancer Cells
Current Pharmaceutical Analysis Purification and Characterization of a Novel Anti-Proliferative Lectin from Morus alba L. Leaves
Protein & Peptide Letters Targeting Nanoparticles as Drug Delivery Systems for Cancer Treatment
Current Nanoscience Indian Indigenous Fruits as Radioprotective Agents: Past, Present and Future
Anti-Cancer Agents in Medicinal Chemistry The Emerging Role of microRNA in Stroke
Current Topics in Medicinal Chemistry Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents
Current Medicinal Chemistry Natural Flora and Anticancer Regime: Milestones and Roadmap
Anti-Cancer Agents in Medicinal Chemistry Hardware and Software Approaches to Multi-Modality Imaging
Current Medical Imaging Retinoids in Cancer Chemoprevention
Current Cancer Drug Targets New Approaches to the Modulation of the Cyclooxygenase-2 and 5-Lipoxygenase Pathways
Current Topics in Medicinal Chemistry Application of the Shortest Path Algorithm for the Discovery of Breast Cancer-Related Genes
Current Bioinformatics MicroRNAs in Breast Cancer Therapy
Current Pharmaceutical Design Metabolic Features of Melanoma: A Gold Mine of New Therapeutic Targets?
Current Cancer Drug Targets MicroRNA-203: Tumor Suppression and Beyond
MicroRNA Genetics and Bioenergetics of Mitochondria Influencing the Etiology and Pharmacology of Steroidal Hormones
Current Pharmacogenomics SCF E3 Ubiquitin Ligases as Anticancer Targets
Current Cancer Drug Targets